Legend Biotech (LEGN)
(Real Time Quote from BATS)
$44.26 USD
+0.93 (2.15%)
Updated May 31, 2024 10:18 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LEGN 44.26 +0.93(2.15%)
Will LEGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LEGN
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Legend Biotech (LEGN) Stock Might be a Great Pick
Company News for Mar 12, 2024
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for LEGN
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
Jefferies Issues a Buy Rating on Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Merus (MRUS) and Agilon Health (AGL)
Legend Biotech price target lowered by $13 at H.C. Wainwright, here's why
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA